体外血液吸附治疗在心脏手术中的死亡率和不良事件:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入12项RCT共713例成人心脏手术患者,比较体外血液吸附(HA)与常规体外循环(CPB)。结果显示HA对死亡率、住院时间、ICU停留时间及不良事件均无显著改善,但因置信区间较宽,不能排除临床相关获益或危害。
要点
- HA未显著降低心脏手术患者死亡率(OR 1.08,95%CI 0.59-2.01,P=0.75)。
- HA未显著缩短住院时间(MD 0.21,95%CI -1.89-2.30,P=0.82)及ICU停留时间(MD -0.36,95%CI -1.31-0.60,P=0.42)。
- 不良事件及通气、心血管支持、肾脏替代治疗需求无显著差异。
核心结论
- 该系统综述与Meta分析未显示常规使用HA在心脏手术中具有临床获益,但现有证据不能排除临床相关获益或危害。
研究设计与样本
- 系统综述与Meta分析纳入12项随机对照试验(RCT),共713例接受体外循环(CPB)的成人心脏手术患者。
- 干预为在CPB回路中插入HA,对照为常规CPB不加HA。
主要发现
- HA组与对照组死亡率无统计学显著差异(OR 1.08,95%CI 0.59-2.01,P=0.75)。
- 住院时间无显著差异(MD 0.21,95%CI -1.89-2.30,P=0.82)。
- ICU停留时间无显著差异(MD -0.36,95%CI -1.31-0.60,P=0.42)。
- 不良事件及通气、心血管支持、肾脏替代治疗需求无显著差异。
关键数值与推荐
- 仅1项研究为低偏倚风险,限制了结果的强度。
- 主要结局死亡率的OR为1.08(95%CI 0.59-2.01,P=0.75)。
临床怎么用
- 现有证据不支持在心脏手术CPB中常规使用HA。
- 临床决策应个体化,尤其针对细胞因子负荷高风险患者需等待更多证据。
局限性
- 仅1项研究为低偏倚风险,整体证据质量受限。
- 置信区间较宽,不能排除临床相关获益或危害。
- 需要针对细胞因子负荷最高风险患者开展足够效能的RCT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extracorporeal haemoadsorption (HA) therapy has been studied in RCTs for use during cardiopulmonary bypass (CPB). CPB is known to activate a systemic inflammatory response. Haemoadsorption has the potential to mitigate this through the removal of pro-inflammatory mediators. We aimed to examine available RCT data reporting on clinically important outcomes in a systematic review and meta-analysis. METHODS: We performed a systematic review and meta-analysis involving adult patients undergoing cardiac surgery with the use of CPB. The intervention was HA inserted into the CPB circuit, and the comparator was conventional CPB without HA. The primary outcome was mortality, and secondary outcomes included adverse events, requirements for organ support, and length of stay in ICU and hospitals. RESULTS: We included 12 RCTs with 713 participants. Only one study had low risk of bias, limiting the strength of findings. Meta-analysis showed no statistically significant benefit of HA during CPB on mortality (odds in the intervention vs control group (odds ratio, 95% confidence interval [CI]=1.08, 0.59-2.01, P=0.75), hospital length of stay (mean difference of the intervention vs control group (pooled mean difference, 95% CI=0.21, -1.89-2.30, P=0.82) and intensive care length of stay (mean difference of the intervention vs control group (pooled mean difference, 95% CI=-0.36, -1.31-0.60, P=0.42) when compared with standard CPB. However, confidence intervals included the possibility of clinically important benefit or harm. There was also no significant difference in adverse events or requirements for ventilation, cardiovascular support or renal replacement therapy. CONCLUSIONS: This meta-analysis did not show evidence of clinical benefit for routine use of HA during CPB for cardiac surgery, although clinically relevant benefit or harm cannot be excluded on the currently available evidence. Appropriately powered and clinically focused RCTs targeting cases at the highest risk of cytokine burden are required.
引用
- Pittaway HCA, Kelly JM, Price MJ, et al. Mortality and adverse events of extracorporeal haemoadsorption therapy in cardiac surgery: a systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. 2026. PMID: 42481274. doi:10.1016/j.bja.2026.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。